Were the Karyopharm (KPTI) share sales by Mano Michael part of a trading plan?

Yes. The sale was made under a durable automatic sale instruction plan adopted on May 16, 2022. This structure means the transaction was pre-arranged and focused on covering tax obligations rather than reflecting a new discretionary decision to sell shares.

Karyopharm (KPTI) EVP sale covers tax on earned PSU award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. executive Mano Michael, EVP, CLO & Secretary, reported a small automatic share sale tied to a performance-based equity award. On May 13, 2026, he acquired 700 shares of common stock via earned performance-based restricted stock units (PSUs) granted in February 2024, after a clinical enrollment milestone in the Phase 3 XPORT-EC-042 trial was certified as achieved.

On May 14, 2026, 266 shares of common stock were sold at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan adopted on May 16, 2022, solely to cover withholding tax liability from the PSU vesting. Following these transactions, Michael directly owns 94,398 shares of Karyopharm common stock.

Insider Trade Summary

Net Seller: 266 shares ($2,527)

Net Sell 2 txns

Insider Mano Michael

Role EVP, CLO&Secretary

Sold 266 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock	266	$9.50	$3K
Grant/Award	Common Stock	700	$0.00	--

Holdings After Transaction: Common Stock — 94,398 shares (Direct, null)

Footnotes (1)

Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

Key Figures

Shares sold: 266 shares Sale price: $9.50 per share PSUs earned and vested: 700 shares +3 more

6 metrics

Shares sold 266 shares Open-market sale on May 14, 2026 at $9.50 per share

Sale price $9.50 per share Broker-assisted tax-withholding sale on May 14, 2026

PSUs earned and vested 700 shares Performance-based RSUs earned and vested on May 13, 2026

Post-transaction holdings 94,398 shares Common stock directly owned after reported transactions

Trading plan adoption date May 16, 2022 Durable automatic sale instruction plan start date

Trial milestone Phase 3 XPORT-EC-042 enrollment Clinical enrollment milestone for earning PSUs

Key Terms

performance-based restricted stock units, PSUs, Phase 3 XPORT-EC-042 trial, durable automatic sale instruction plan, +2 more

6 terms

performance-based restricted stock units financial

"Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs")"

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

PSUs financial

"Each earned PSU represents the contingent right to receive one share of the issuer's common stock"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

Phase 3 XPORT-EC-042 trial medical

"achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial"

durable automatic sale instruction plan financial

"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person"

withholding tax liability financial

"represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs"

broker-assisted sale financial

"represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability"

Form 4 Insider Transactions: What Each Field Means →

05/15/2026 - 04:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mano Michael

(Last)

(First)

(Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON

MASSACHUSETTS

02459

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, CLO&Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/13/2026		A		700⁽¹⁾	A	$0.0	94,664	D
Common Stock	05/14/2026		S⁽²⁾		266	D	$9.5	94,398	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.

2. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Michael Mano	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Karyopharm (KPTI) EVP Mano Michael report?

Mano Michael reported earning 700 shares from performance-based restricted stock units and selling 266 shares. The sale occurred at $9.50 per share and was executed to cover tax withholding obligations tied to the PSU vesting under a pre-established automatic plan.

How many Karyopharm (KPTI) shares does Mano Michael hold after this Form 4?

After these transactions, Mano Michael directly holds 94,398 Karyopharm common shares. This reflects the net effect of 700 shares acquired from earned PSUs and 266 shares sold to satisfy withholding tax, indicating a relatively small reduction versus his overall position.

Why did Karyopharm (KPTI) EVP Mano Michael sell 266 shares?

The 266-share sale at $9.50 per share was to pay withholding tax on vested PSUs. It was executed as a broker-assisted transaction under a durable automatic sale instruction plan, so it did not represent a discretionary market-timing decision by the executive.

What performance milestone triggered the Karyopharm (KPTI) PSU award for Mano Michael?

The PSU award was earned based on achieving a clinical milestone for complete enrollment in Karyopharm’s Phase 3 XPORT-EC-042 trial. The Compensation Committee certified this achievement on May 13, 2026, leading to 700 PSUs earning and vesting into common shares.

What type of equity award did Karyopharm (KPTI) grant to Mano Michael?

Karyopharm granted performance-based restricted stock units (PSUs) in February 2024. Each earned PSU provides a contingent right to receive one share of common stock, which in this case resulted in 700 shares vesting once the specified Phase 3 trial enrollment milestone was achieved.